Skip to content
★ Sign in to follow
RP

Renhe Pharmacy Co.,Ltd Stock: price and insider trades · China

仁和药业

CN·Mcap CN¥7.2BHealth Care

No insider purchase over the last 90 days. The latest, by 杨潇, was filed 01 Nov 2023.

Renhe Pharmacy Co.,Ltd: what insiders have been doing

Renhe Pharmacy Co.,Ltd is a Health Care company based in People's Republic of China. Its directors and officers file their transactions with SSE / SZSE (CSRC). Nothing new has been filed by managers of Renhe Pharmacy Co.,Ltd in twelve months, the latest record being from 1 November 2023.

Our records for Renhe Pharmacy Co.,Ltd go back to 2023, with 9 purchases and no sales on the open market in total.

Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and Vetoquinol SA. This summary is built from SSE / SZSE (CSRC) disclosures alone and does not predict where the share price will go.

Key facts

Headquarters: People's Republic of China

Source: Wikidata (CC0).

Insider Decl.
9
Thresholds
n/a
Buy Volume
€13M
9 ops. · all time
Sell Volume
n/a
n/a

Since the insiders bought

  • Filed 01 Nov 2023 · 1105 days ago · €504k
    -16.8%
    Entry CN¥6.85 · Close at T+365 CN¥5.70

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 4,245 of 26,911 companies
69.7
score / 100
Value
69
Quality
70
FCF yld11%
Earn yld5.4%
EV/EBITDA9.3x
ROE6.9%
Gross mgn37%
Net mgn11%
Debt/EBITDA0.0x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

CN¥5.16
Analyst consensus
·
Income statement
RevenueCN¥3.5B
Gross profitCN¥1.3B37% margin
EBITDACN¥780.8M22% margin
Net incomeCN¥393.2M10.8% margin
Valuation
PER (trailing)18.4x
P/Book1.1x
Beta0.33
Balance sheet & cash
Market capCN¥7.2B
Total debtCN¥2.2M
Free Cash FlowCN¥776.7M
Debt / Equity0%
Profitability & ownership
ROE6.9%
ROA4.4%
% insiders32.5%
% institutions1.9%
Last declaration on 1 November 2023
Declarations9 total
  • ▲
    董事Executives
    4M CNY7SZSE
    560,000 shares4.0% of flowA股XSHESZSE:173000007057391260
    Canonical exit: 30 Jan 2024 (T+90)
  • ▲
    董事Executives
    9M CNY8SZSE
    1,300,000 shares9.5% of flowA股XSHESZSE:173000007054267330
    Canonical exit: 29 Jan 2024 (T+90)
  • ▲
    董事Executives
    31M CNY10SZSE
    4,427,500 shares32.6% of flowA股XSHESZSE:173000007051128960
    Canonical exit: 28 Jan 2024 (T+90)
  • ▲
    董事Executives
    23M CNY9SZSE
    3,146,900 shares23.9% of flowA股XSHESZSE:173000006991606460
    Canonical exit: 27 Dec 2023 (T+90)
  • ▲
    董事Executives
    5M CNY7SZSE
    660,000 shares4.8% of flowA股XSHESZSE:173000006953737440
    Canonical exit: 19 Dec 2023 (T+90)
  • ▲
    董事Executives
    6M CNY8SZSE
    940,000 shares6.4% of flowA股XSHESZSE:173000006909179360
    Canonical exit: 6 Dec 2023 (T+90)
  • ▲
    董事Executives
    3M CNY7SZSE
    460,000 shares3.3% of flowA股XSHESZSE:173000006903481820
    Canonical exit: 4 Dec 2023 (T+90)
  • ▲
    董事Executives
    8M CNY8SZSE
    1,253,100 shares8.6% of flowA股XSHESZSE:173000006862917340
    Canonical exit: 26 Nov 2023 (T+90)
  • ▲
    董事Executives
    7M CNY8SZSE
    1,020,200 shares7.0% of flowA股XSHESZSE:173000006854778340
    Canonical exit: 23 Nov 2023 (T+90)

9 of 9 declarations

About Renhe Pharmacy Co.,Ltd

仁和药业 is a company operating in the health and pharmaceutical sector, listed on the XSHE market. It focuses on the development and production of medicines and health products.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations